AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SA...
AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SAFETY IN A PHASE 2 STUDY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
About this item
Full title
Author / Creator
Ide, T. , Chiney, M. , Bach, H. Y. T. , Goti, V. , Murthy, B. , Hobar, C. , Zhao, Q. and Aras, U.
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd and European League Against Rheumatism
Subjects
More information
Scope and Contents
Contents
BackgroundDeucravacitinib is a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor approved in multiple countries for the treatment of adults with plaque psoriasis [1,2]. Deucravacitinib binds to the unique TYK2 regulatory domain, conferring greater functional selectivity vs JAK inhibitors, which bind to the catalytic dom...
Alternative Titles
Full title
AB0515 PHARMACOKINETICS, SELECTIVITY PROFILE, AND EXPOSURE-RESPONSE RELATIONSHIP FOR EFFICACY AND SAFETY IN A PHASE 2 STUDY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2822137756
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2822137756
Other Identifiers
ISSN
0003-4967
E-ISSN
1468-2060
DOI
10.1136/annrheumdis-2023-eular.1714
